Literature DB >> 9210691

Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis.

J C Ding1, M Bauer, D M Diamond, M A Leal, D Johnson, B K Williams, A M Thomas, L Najvar, J R Graybill, R A Larsen.   

Abstract

We studied the effect of the severity of meningitis on the response to therapy with fluconazole and flucytosine in a murine model of cryptococcal meningitis. Meningitis was established by intracerebral injection of Cryptococcus neoformans. The severity of meningitis was varied by delaying the onset of treatment from 3 to 7 days. Animals were sacrificed after 14 days of treatment, and the numbers of C. neoformans per gram of brain tissue were quantified. The range of effective dose combinations of fluconazole and flucytosine became progressively reduced as the severity of meningitis increased. The magnitude of treatment effect, as measured by the numbers of CFU/gram of brain tissue, was also reduced with increasing severity of meningitis. In this model, as the severity of meningitis increases, higher doses of fluconazole are required to achieve equivalent levels of activity. The combination of fluconazole and flucytosine appears to have the most-potent antifungal effects. This is most readily observed in animals with more-severe meningitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9210691      PMCID: PMC163965     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro studies with combinations of 5-fluorocytosine and amphotericin B.

Authors:  S Shadomy; G Wagner; E Espinel-Ingroff; B A Davis
Journal:  Antimicrob Agents Chemother       Date:  1975-08       Impact factor: 5.191

2.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Authors:  M S Saag; W G Powderly; G A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; J F Fisher
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

3.  Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial.

Authors:  R A Larsen; M A Leal; L S Chan
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

4.  Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis.

Authors:  R A Larsen; M Bauer; J M Weiner; D M Diamond; M E Leal; J C Ding; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis.

Authors:  J E Bennett; W E Dismukes; R J Duma; G Medoff; M A Sande; H Gallis; J Leonard; B T Fields; M Bradshaw; H Haywood; Z A McGee; T R Cate; C G Cobbs; J F Warner; D W Alling
Journal:  N Engl J Med       Date:  1979-07-19       Impact factor: 91.245

6.  Confidence intervals for the survival function using Cox's proportional-hazard model with covariates.

Authors:  C L Link
Journal:  Biometrics       Date:  1984-09       Impact factor: 2.571

7.  Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis.

Authors:  R Allendoerfer; A J Marquis; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

8.  Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS.

Authors:  A J Berry; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

9.  Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

Authors:  R A Larsen; S A Bozzette; B E Jones; D Haghighat; M A Leal; D Forthal; M Bauer; J G Tilles; J A McCutchan; J M Leedom
Journal:  Clin Infect Dis       Date:  1994-10       Impact factor: 9.079

10.  In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans.

Authors:  M H Nguyen; F Barchiesi; D A McGough; V L Yu; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

  10 in total
  28 in total

1.  In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 2.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 3.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Combination antifungal therapy for the treatment of invasive yeast and mold infections.

Authors:  John W Baddley; Peter G Pappas
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

6.  Differential changes in junctional complex proteins suggest the ependymal lining as the main source of leukocyte infiltration into ventricles in murine neurocysticercosis.

Authors:  Jorge I Alvarez; Judy M Teale
Journal:  J Neuroimmunol       Date:  2007-06-26       Impact factor: 3.478

7.  Multiple expression of matrix metalloproteinases in murine neurocysticercosis: Implications for leukocyte migration through multiple central nervous system barriers.

Authors:  Jorge I Alvarez; Judy M Teale
Journal:  Brain Res       Date:  2008-04-01       Impact factor: 3.252

8.  A murine model of Cryptococcus gattii meningoencephalitis.

Authors:  George R Thompson; Nathan P Wiederhold; Laura K Najvar; Rosie Bocanegra; William R Kirkpatrick; John R Graybill; Thomas F Patterson
Journal:  J Antimicrob Chemother       Date:  2012-02-29       Impact factor: 5.790

Review 9.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

10.  Interactions of posaconazole and flucytosine against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; L K Najvar; R Bocanegra; F Caselli; S Di Cesare; D Giannini; L F Di Francesco; A Giacometti; F Carle; G Scalise; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.